

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

ROXADUSTAT CAPSULES OBTAIN DRUG REGISTRATION APPROVAL

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Roxadustat Capsules (20mg/50mg) (the “**Product**”) developed by the Group has obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China. The Product is the first generic drug of its kind that has been approved in China, and is deemed to have passed the consistency evaluation of quality and efficacy for generic drugs.

Roxadustat is the world’s first hypoxia-inducible factor-prolyl hydroxylase inhibitor (HIF-PHI), which is suitable for anemia caused by chronic kidney disease (CKD) in patients receiving dialysis and non-dialysis treatment. As a new generation oral drug for the treatment of renal anemia with novel mechanism, Roxadustat corrects anemia by activating the HIF pathway that promotes endogenous erythropoietin (EPO) production, reduces the hepcidin levels, and improves iron absorption, transport and utilisation. Roxadustat received the highest level (Level 1A) of recommendation in the Clinical Practice Guidelines for the Diagnosis and Treatment of Renal Anemia in China* (中國腎性貧血診治臨床實踐指南) and the Chinese Expert Consensus on the Treatment of Renal Anemia with Roxadustat* (羅沙司他治療腎性貧血中國專家共識).

The approval of the Product will further enrich the Group’s product portfolio for blood and hemopoietic system treatment and provide patients with new options.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 5 July 2024

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. JIANG Hao, Dr. YAO Bing and Mr. CAI Xin as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.

** For identification purpose only*